Pharmacologic treatments for covid-19 patients

Nezulcitinib (TD-0903) vs Placebo


Hospitalized patients

Forest plots
(last update: 2022-10-07)

Summary of findings
(last update: 2022-10-14)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=307

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04402866
NCT04402866, Unpublished, 2022
Full text
Not reported/unclear

Nezulcitinib (TD-0903)

Placebo

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in Brazil, Moldova, Finland, Romania, Ukraine, UK, and USA. N=210
Some concerns
Details

Full description

NCT04402866; EudraCT 2020-001807-18
Singh D, medRxiv, 2021
Full text
Commentary
Commentary
Private

Nezulcitinib (TD-0903) 3 mg

Placebo

RCT Patients with confirmed COVID-19 (moderate) admitted to centers in Moldova, UK and Ukraine. N=25
Some concerns
Details

Full description